XML 47 R35.htm IDEA: XBRL DOCUMENT
v3.23.3

Collaboration and License Agreements - Additional Information (Details) $ in Thousands |  | 3 Months Ended | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Feb. 08, 2023 | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Dec. 31, 2021 USD ($) program | Dec. 31, 2020 program | Dec. 31, 2022 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Number of programs the collaboration to focus on | program |  |  |  |  |  |  | 3 |
Accrued and other liabilities |  | $ 146,111 |  | $ 146,111 |  |  |  | $ 489,090
Research and development |  | 148,253 | $ 114,166 | 477,756 | $ 319,475 |  |  |
Total unrecognized transaction price |  | 53,207 |  | 53,207 |  |  |  | $ 53,207
2020 GSK |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Payments to GSK |  | 67,000 |  | 340,500 |  |  |  |
Accrued and other liabilities |  | 900 |  | 900 |  |  |  |
Research and development |  | 6,100 | 10,400 | 18,600 | 24,000 |  |  |
Preliminary Collaboration Agreement | 2020 GSK | Antibody Program |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Percentage of development costs | 72.50% |  |  |  |  |  |  |
2021 Collaboration Agreement | 2021 GSK |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Number of separate programs | program |  |  |  |  |  | 3 |  |
Option exercise fee to be received |  |  |  |  |  | $ 300,000 |  |
2021 Collaboration Agreement | 2021 GSK | Maximum |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Pre-defined regulatory milestone payment |  |  |  |  |  | $ 200,000 |  |
2021 GSK Collaboration |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Research and development |  | 600 | $ 300 | 1,900 | $ 1,300 |  |  |
Percentage of share development costs |  |  |  |  |  | 50.00% |  |
Percentage of share Profit and loss |  |  |  |  |  | 50.00% |  |
Total unrecognized transaction price |  | $ 51,700 |  | $ 51,700 |  |  |  |

X
- Definition Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + References No definition available. + Details
Name: | us-gaap_AccruedLiabilitiesAndOtherLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration agreement, number of separate programs agreed to collaborate. + References No definition available. + Details
Name: | vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate
Namespace Prefix: | vir_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of Programs the Collaboration is to Focus On + References No definition available. + Details
Name: | vir_NumberOfProgramsTheCollaborationIsToFocusOn
Namespace Prefix: | vir_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Option exercise fee consideration to be received. + References No definition available. + Details
Name: | vir_OptionExerciseFeeConsiderationToBeReceived
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Payments to Counterparty + References No definition available. + Details
Name: | vir_PaymentsToCounterparty
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of development costs. + References No definition available. + Details
Name: | vir_PercentageOfDevelopmentCosts
Namespace Prefix: | vir_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of share development costs. + References No definition available. + Details
Name: | vir_PercentageOfShareDevelopmentCosts
Namespace Prefix: | vir_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Pre-Defined Regulatory Milestone Consideration To Be Received + References No definition available. + Details
Name: | vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Profits and losses sharing percentage. + References No definition available. + Details
Name: | vir_ProfitsAndLossesSharingPercentage
Namespace Prefix: | vir_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_AntibodyProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyOneCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |